Clene Inc.
CLNN
Positions held
Your positionsCLNN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $55.15M | Enterprise value | $62.53M | Trailing P/E | — | Forward P/E | -1.59 |
| PEG | — | Price / book | -2.00 | Beta | 0.92 | Dividend yield | 0.00% |
| Revenue growth | 2.3% | Earnings growth | — | Gross margin | 70.1% | Operating margin | -59.4% |
| Profit margin | 0.0% | ROE | — | ROA | -56.9% | Debt / equity | — |
| Current ratio | 3.07 | Free cash flow | -$9.87M | Analyst recommendation | none | Mean target | $32.20 |
| 52w high | $13.50 | 52w low | $3.25 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | $0.0M | $0.1M | $0.0M | $0.0M | — |
| Op margin | -5737.8% | -11280.0% | -9407.8% | -35820.0% | -20844.4% | — |
| Net income | -$13.4M | -$8.1M | -$9.2M | -$8.8M | -$7.4M | — |
| Gross margin | 60.0% | 100.0% | 70.1% | 100.0% | 100.0% | — |
| Gross profit | $0.1M | $0.0M | $0.1M | $0.0M | $0.0M | — |
| Operating income | -$5.2M | -$1.7M | -$7.2M | -$5.4M | -$5.6M | — |
- Revenue +500% vs prior quarter ($0.1M vs $0.0M).
- Gross margin 60% (was 100% prior quarter).
- Operating margin expanded to -5737.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.2M | $0.3M | $0.7M | $0.5M | — |
| Op margin | -10908.0% | -9349.4% | -5850.2% | -9420.1% | — |
| Net income | -$26.2M | -$39.4M | -$49.5M | -$29.9M | — |
| Gross margin | 78.5% | 79.5% | 81.5% | 94.5% | — |
| Gross profit | $0.2M | $0.3M | $0.5M | $0.4M | — |
| Operating income | -$21.8M | -$32.0M | -$38.3M | -$44.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision
2026-09-22 · Clene to Present at Upcoming Investor Conferences
2026-09-15 · Top Midday Gainers
2026-09-15 · Clene Announces $4 Million Registered Direct Offering
2026-09-03 · Clene to Present at Upcoming September Investor Conferences
2026-08-19 · Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses
2026-08-18 · Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream
2026-08-17 · Clene to Present at the Emerging Growth Conference
2026-08-14 · Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates
2026-08-14 · Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
2026-08-12 · Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS
Price (daily)
Full chart · RSI · MACD · patterns